An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study

Trial Profile

An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Onartuzumab (Primary) ; Bevacizumab; Erlotinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 23 Nov 2017 Planned End Date changed from 22 Aug 2017 to 25 Jan 2018.
    • 23 Nov 2017 Planned primary completion date changed from 22 Aug 2017 to 25 Jan 2018.
    • 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top